On August 1, 2012, Ouyang, Wuqing; Zhou, Ying; Ouyang, Shenyu published a patent.Electric Literature of 23256-42-0 The title of the patent was Rifaximin and trimethoprim lactate compounded nanoemulsion and its preparation method. And the patent contained the following:
The compounded nanoemulsion is composed of surfactant 30-45, cosurfactant 1-10, oil phase 1-16, rifaximin 0.1-5, trimethoprim lactate 0.025-1.25 wt%, and addnl. deionized water. The surfactant is one or more of EL-40, RH-40, Tween-80, and poloxamer 188. The cosurfactant is one or more of anhydrous ethanol, 1,2-propanediol, glycerol, and polyethylene glycol-400. The oil phase is one or more of iso-Pr myristate, glyceryl triacetate, Et oleate, wheat germ oil, Et acetate, and Bu acetate. The preparation method comprises weighing surfactant, cosurfactant, oil phase, rifaximin, trimethoprim lactate and deionized water according to the formula, mixing surfactant with cosurfactant, then adding oil phase, mixing, adding rifaximin, mixing, adding trimethoprim lactate, mixing, and adding deionized water while stirring. This nanoemulsion is suitable for treatment of acute and chronic intestinal tract infection, diarrhea syndrome, etc., and has the characteristics of rapid and persistent effect, high safety and wide market prospect. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Electric Literature of 23256-42-0
The Article related to rifaximin trimethoprim lactate compounded nanoemulsion acute diarrhea composition, Pharmaceuticals: Formulation and Compounding and other aspects.Electric Literature of 23256-42-0
Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia